



## **Minimising Avoidable Expenditure and the Risk of Fraud & Error from Prescribing and Dispensing Expensive Items**

**Approved by:** Pharmacy & Medicines Management Division Governance Group 4<sup>th</sup> November 2024 (Chairs action)

**Domain 1 - Ensuring ongoing clinical appropriateness**

Key Controls	Assurance	Oversight
<ul style="list-style-type: none"> <li>• Primary Care Medicines Management Team supporting Clusters and individual GP Practices to achieve evidence and value based prescribing.</li> <li>• Head of Medicines Governance &amp; Optimising Medicines Value in post (review of WP10HP prescribing included within portfolio).</li> <li>• ScriptSwitch messaging software linked to all GP practices in the SBU Health Board area.</li> <li>• Primary care based prescribing support dietician in post to facilitate prudent oral nutritional supplement prescribing.</li> <li>• Home enteral feeding contractor delivers care under an All-Wales service specification that includes provision to alert the dietetic team in the event of potential changes in prescription reported by the patient.</li> <li>• All adult patients are able to access the Health Board’s Healthy Bladder and Bowel Service (HB&amp;BS). Patients who opt out of this service remain under the care of their GP.</li> <li>• All patients receiving appliances from the HB&amp;BS are offered an annual review to assess ongoing clinical appropriateness of prescribing. Continence products are prescribed against an appliance formulary (updated annually) by registered V150 nurse prescribers.</li> <li>• The HB&amp;BS are repatriating anal irrigation prescribing by mid-November 2024 to improve oversight of this prescribing.</li> </ul>	<ul style="list-style-type: none"> <li>• Quarterly review of <a href="#">WAPSU Expensive Items Dashboard</a> with corresponding follow up to ensure annual review of ongoing clinical appropriateness for individual patients. Any exceptions found will be flagged for review by the appropriate clinician/service.</li> <li>• ScriptSwitch messages regularly reviewed and updated to support decision making around clinical appropriateness of prescribing.</li> <li>• Quarterly performance review of the home enteral feeding contractor by the Health Board which include monitoring of KPIs.</li> <li>• Bi-annual performance review between home enteral feeding contractor and NWSSP.</li> <li>• HB&amp;BS patient management system monitors compliance with annual review of patients, flagging exceptions for follow up.</li> </ul>	<ul style="list-style-type: none"> <li>• Annual report to the Pharmacy &amp; Medicines Management Division Governance Group</li> </ul>

**Domain 2 - Ensuring ongoing appropriateness of ordering and supply**

Key Controls	Sources of assurance level 1	Oversight
<ul style="list-style-type: none"> <li>• Primary Care Medicines Management Team (MMT) supporting Clusters and individual GP Practices to achieve evidence and value based prescribing.</li> <li>• Head of Medicines Governance &amp; Optimising Medicines Value in post (review of WP10HP prescribing included within portfolio).</li> <li>• ScriptSwitch messaging software linked to all GP practices in the SBU Health Board area.</li> <li>• Primary care based prescribing support dietician in post to facilitate prudent oral nutritional supplement prescribing.</li> <li>• Home enteral feeding contractor delivers care under an All-Wales service specification that includes completion of monthly online or telephone stock checks and provision to alert the dietetic team in the event of non-receipt of prescription.</li> <li>• All adult patients are able to access the Health Board’s Healthy Bladder and Bowel Service (HB&amp;BS). Patients who opt out of this service remain under the care of their GP.</li> <li>• HB&amp;BS retain prescribing of continence products and the patient management system is able to track quantities and frequency supplied.</li> <li>• The HB&amp;BS are repatriating anal irrigation prescribing by mid-November 2024 to improve oversight of this prescribing.</li> </ul>	<ul style="list-style-type: none"> <li>• Quarterly review of <a href="#">WAPSU Expensive Items Dashboard</a> with corresponding follow up to ensure quantities prescribed and ordering frequency are in line with prescribed directions on an annual basis for individual patients. Any exceptions found will corrected by the MMT and/or flagged for review by the appropriate clinician/service.</li> <li>• ScriptSwitch messages regularly reviewed and updated to support appropriateness of quantity supplied.</li> <li>• Quarterly performance review of the home enteral feeding contractor by the Health Board which include monitoring of KPIs.</li> <li>• Bi-annual performance review between home enteral feeding contractor and NWSSP.</li> <li>• HB&amp;BS patient management system monitors quantity and frequency of prescription requests flagging exceptions for follow up.</li> </ul>	<ul style="list-style-type: none"> <li>• Annual report to the Pharmacy &amp; Medicines Management Division Governance Group</li> </ul>

**Domain 3 - Ensuring ongoing cost-effective prescribing/dispensing**

Key Controls	Sources of assurance level 1	Oversight
<ul style="list-style-type: none"> <li>• Primary Care Medicines Management Team (MMT) supporting Clusters and individual GP Practices to achieve evidence and value based prescribing.</li> <li>• Head of Medicines Governance &amp; Optimising Medicines Value in post (review of WP10HP prescribing included within portfolio).</li> <li>• ScriptSwitch messaging software linked to all GP practices in the SBU Health Board area.</li> <li>• Health Board Community Pharmacy Professional Lead in post to support liaison between community pharmacy teams and the MMT.</li> <li>• E-schedule data available to Health Boards detailing Out of Pocket expenses claimed by community pharmacies.</li> <li>• Quarterly Health Board Medicines Management and Community Pharmacy Newsletters distributed to all community pharmacies within the SBU Health Board area.</li> </ul>	<ul style="list-style-type: none"> <li>• Quarterly review of <a href="#">WAPSU Expensive Items Dashboard</a> with corresponding follow up to ensure product choice represents a best value decision. Any exceptions found will be flagged for review by the appropriate clinician/service.</li> <li>• ScriptSwitch messages regularly reviewed and updated to support cost effective prescribing.</li> <li>• High-cost special order items will be discussed with individual community pharmacies to support cost effective procurement.</li> <li>• Quarterly audit of Out-of-Pocket Expenses claimed by community pharmacies relating to expensive items.</li> <li>• Periodic awareness raising via the Community Pharmacy Newsletter highlighting requirement to make the prescriber aware when they have prescribed a medicine that is only available as a special order un-licensed product and to make appropriate annotations on prescriptions when claiming Out of Pocket expenses to support audit.</li> </ul>	<ul style="list-style-type: none"> <li>• Annual report to the Pharmacy &amp; Medicines Management Division Governance Group</li> </ul>